Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 15/20 | 0.54 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14840622 | 0.89 | CYP46A1 (0.67) | CYP46A1AVPR1ACYP2C19CYP3A4CYP2C8 | |
| SCHEMBL14849114 | 0.88 | CYP46A1 (0.57) | CYP46A1AVPR1ACYP2C19CYP3A4CYP2C8 | |
| SCHEMBL14871789 | 0.88 | CYP46A1 (0.47) | CYP46A1CYP2C19CYP3A4CYP2C9MAPK1 | |
| SCHEMBL14849066 | 0.83 | CYP46A1 (0.52) | CYP46A1AVPR1ACYP2C19CYP3A4CYP2C8 | |
| SCHEMBL14840628 | 0.83 | CYP46A1 (0.79) | CYP46A1AVPR1ACYP2C19CYP3A4CYP2C8 | |
| SCHEMBL14849116 | 0.80 | CYP46A1 (0.70) | CYP46A1AVPR1ACYP2C19CYP3A4CYP2C8 | |
| SCHEMBL14840550 | 0.80 | CYP46A1 (0.80) | CYP46A1AVPR1ACYP2C19CYP3A4CYP2C8 | |
| SCHEMBL14871788 | 0.77 | CYP46A1 (0.42) | CYP46A1CYP3A4 | |
| SCHEMBL14840316 | 0.77 | CYP46A1 (0.49) | CYP46A1AVPR1ACYP2C19CYP3A4CYP2C8 | |
| SCHEMBL14840729 | 0.74 | CYP46A1 (0.78) | CYP46A1AVPR1ACYP2C19CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174272-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| US-11174272-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20210206781-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2021-07-08 | — | — | US | disclosed |
| US-20210206781-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2021-07-08 | — | — | US | disclosed |
| US-10717748-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-21 | — | — | US | disclosed |
| US-10717748-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-21 | — | — | US | disclosed |
| US-20200157117-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-21 | — | — | US | disclosed |
| US-20200157117-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-21 | — | — | US | disclosed |
| US-10550129-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-04 | — | — | US | disclosed |
| US-10550129-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-04 | — | — | US | disclosed |
| US-20140088118-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-27 | — | — | US | disclosed |
| US-20140088118-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-27 | — | — | US | disclosed |
| US-20140088146-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-27 | — | — | US | disclosed |
| US-20140088118-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-27 | — | — | US | disclosed |
| US-8648079-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-02-11 | — | — | US | disclosed |
| US-8648079-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-02-11 | — | — | US | disclosed |
| US-8648079-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20130090341-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-11 | — | — | US | disclosed |
| US-20130090341-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-11 | — | — | US | disclosed |
| US-20130090341-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157117-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | CYP46A1 3780/4885AVPR1A 3346/4885CYP2C19 4412/4885 |
| US-11174272-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | CYP46A1 3780/4885AVPR1A 3346/4885CYP2C19 4412/4885 |
| US-10717748-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | CYP46A1 3780/4885AVPR1A 3346/4885CYP2C19 4412/4885 |
| US-20140088118-A1 | HETEROCYCLIC COMPOUNDS | HTT, NQO1, BDNF | CYP46A1 1579/4885AVPR1A 2353/4885CYP2C19 2980/4885 |
| US-20130090341-A1 | HETEROCYCLIC COMPOUNDS | HTT, NQO1, BDNF | CYP46A1 1579/4885AVPR1A 2353/4885CYP2C19 2980/4885 |
| US-20140088146-A1 | HETEROCYCLIC COMPOUNDS | HTT, NQO1, BDNF | CYP46A1 1579/4885AVPR1A 2353/4885CYP2C19 2980/4885 |
| US-10550129-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | CYP46A1 3780/4885AVPR1A 3346/4885CYP2C19 4412/4885 |
| US-20210206781-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | CYP46A1 3780/4885AVPR1A 3346/4885CYP2C19 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.